Predictive Factors of Endoscopic Mucosal Healing in Quiescent Ulcerative Colitis

Predictive Factors of Endoscopic Mucosal Healing in Quiescent Ulcerative Colitis: Prospective Observational Multicenter Study

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT02640391

Acronym

PINQLE

Enrollment

127

Registered

2015-12-29

Start date

2016-01-31

Completion date

2018-12-31

Last updated

2019-08-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Ulcerative Colitis

Keywords

Ulcerative colitis, fecal calprotectin, mucosal healing

Brief summary

The purpose of this study is to determine whether fecal calprotectin, fecal immunochemical test, and Rome III criteria for irritable bowel syndrome (IBS) can predict mucosal healing in patients with quiescent ulcerative colitis (UC).

Interventions

OTHERcolonoscopy

Study design

Observational model

CASE_ONLY

Time perspective

CROSS_SECTIONAL

Eligibility

Sex/Gender

ALL

Age

18 Years to 80 Years

Healthy volunteers

Inclusion criteria

* Patients with ulcerative colitis who have no change of medication for at least 6 months * Patients with ulcerative colitis who are in remission (Mayo score \<3) * Patients with ulcerative colitis who will undergo colonoscopy for surveillance or mucosal healing check-up

Exclusion criteria

* Patients who refuse to participate * Patients who have a history of colectomy * Patients who have instinal stricture or perforation

Design outcomes

Primary

Measure	Time frame	Description
Fecal calprotectin	1 week	—
Fecal immunochemical test	1 week	—
Mucosal healing	1 week	Endoscopic Mayo subscore \<1

Secondary

Measure	Time frame
Rome III criteria for IBS	1 week

Countries

South Korea

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026